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Class switch recombination (CSR) is a region-specific, transcriptionally regulated, 
nonhomologous recombinational process that is initiated by activation-induced cytidine 
deaminase (AID). The initial lesions in the switch (S) regions are subsequently processed and 
resolved, leading to recombination of the two targeted S regions. The mechanisms by which 
repair and ligation of the broken DNA ends occurs is still elusive. Recently, a small number 
of patients lacking DNA ligase IV, a critical component of the nonhomologous end joining 
(NHEJ) machinery, have been identified. We show that these patients display a considerably 
increased donor/acceptor homology at S
 
 
 
–S
 
 
 
 junctions compared with healthy controls. In 
contrast, S
 
 
 
–S
 
 
 
 junctions show an increased frequency of insertions but no increase in 
junctional homology. These altered patterns of junctional resolution may be related to 
differences in the homology between the S
 
 
 
 and the downstream isotype S regions, and 
could reflect different modes of switch junction resolution when NHEJ is impaired. These 
findings link DNA ligase IV, and thus NHEJ, to CSR.
 
DNA double-strand breaks (DSBs) represent a
serious threat to cell survival and can arise in a
number of ways, such as ionizing radiation,
or as intermediates in normal endogenous
processes including replication, meiosis, and
V(D)J recombination. In response to these
DNA breaks, cells have developed an impres-
sive arsenal of DNA repair pathways. There
are two general types of repair: homologous
recombination (HR) and nonhomologous end
joining (NHEJ). The former includes gene
conversion, break-induced replication, and
single-strand annealing and is predominant in
 
Saccharomyces cerevisiae
 
 and in the G2 phase of
the vertebrate cell cycle. The latter is the prin-
ciple mechanism used in vertebrate cells (1).
Class switch recombination (CSR) is a
programmed gene rearrangement that allows a
B lymphocyte to alter the class of antibody se-
creted, thus changing its biological properties.
It is initiated by activation-induced cytidine
deaminase (AID; reference 2) and resolution of
the DSBs and is thought to rely on the NHEJ
pathway. Based on murine gene targeting
studies, three components of the NHEJ machin-
ery have been implicated in CSR: DNA-PKcs,
Ku70, and Ku80 (for review see reference 3).
However, the impact of the other two com-
ponents, DNA ligase IV and XRCC4, which
are critical to NHEJ, have not been analyzed to
date, as disruption of 
 
LIG4
 
 or 
 
XRCC4
 
 in mice
results in embryonic lethality (4, 5).
A homozygous mutation in 
 
LIG4
 
 was first
described in a developmentally normal leukemia
patient (6). Recently, a few additional patients
with defective DNA ligase IV activity have
been reported with a syndrome consisting of
microcephaly, growth retardation, immuno-
deficiency, and photosensitivity (7). Studies on
cell lines derived from these patients have
shown aberrant, but detectable, levels of V(D)J
recombination (7). These patients provide a
unique opportunity to study the DSB repair
pathways in CSR in the absence of (or with a
markedly reduced level of) DNA ligase IV.
Using our previously developed PCR-based
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Figure 1. PCR amplification of S –S  fragments in Lig4D patients 
and controls. The numbers of S –S  switch fragments were determined 
from 10 PCR reactions run in parallel (lanes 1–10) using DNA from each 
individual. M, molecular weight marker.
 
assay (8), we report that the nature of switch recombination
junctions is altered, showing either a marked shift to utiliza-
tion of microhomologies (
 
 
 
4 bp) (
 
 
 
–
 
 
 
), or an increased fre-
quency of insertions (
 
 
 
–
 
 
 
). This implies that DNA ligase IV
is directly involved in CSR, and when it is defective, alter-
native pathways may be required to repair DSBs.
 
RESULTS AND DISCUSSION
Switching to IgA and IgG in Lig4D patients
 
Genomic DNA was purified from peripheral blood samples
from healthy blood donors and the two Lig4D patients
(411BR and 2304). To determine whether switch recombi-
nation was affected by a lack of functional DNA ligase IV,
individual switch junctions were amplified using a previously
described PCR protocol (8–10). The numbers of S
 
 
 
–S
 
 
 
fragments were determined from 10 PCR reactions run in
parallel using DNA from each individual and can be used as
an estimation of the number of clones that have switched to
IgA. As shown in Fig. 1, when 30 ng of template DNA was
added in each PCR reaction, only two weak bands were
generated from each of the Lig4D patients (Fig. 1, 411BR,
lanes 2 and 3, and 2304, lanes 3 and 7), whereas at least 14
distinct S
 
 
 
–S
 
 
 
 fragments were amplified from the control.
The experiments were repeated independently several times
and the intensity of the smear and the numbers of bands ob-
tained from the patients (ranging from 0 to 2) were consis-
tently less compared with those of the controls.
To estimate the degree of reduction in the number of
switched clones in the patients, we subsequently performed
the same PCRs on a series of dilutions of the DNA tem-
plates from normal individuals (
 
n
 
 
 
  
 
5) and patients. The
average number of S
 
 
 
–S
 
 
 
 fragments generated from con-
trols correlated with the amount of DNA template (r 
 
 
 
0.84, P 
 
  
 
0.05) and 30 ng of DNA input from the patient
was equivalent to 0.37–0.74 ng (41–81-fold less) of the
control samples (Fig. S1 B, available at http://www.jem.org/
cgi/content/full/jem.20040772/DC1). No switch frag-
ment could be amplified from the two patients when DNA
input was 
 
 
 
30 ng (Fig. S1 B). Taking into account that
one patient had lymphopenia (an approximately threefold
reduction) and that the proportion of B cells was low in the
remaining lymphocytes (411BR: 2.6% of PBLs are B cells,
normal controls showing 5–17%), the number of clones
that have switched to IgA appears to be reduced by 
 
 
 
2–14-
fold in this patient. To further estimate the relative propor-
tion of B cells in the peripheral blood, we amplified the
VH-JH rearrangements from the DNA samples used in the
CSR assay. 411BR had a reduced level of rearranged VH
genes (
 
 
 
4–8-fold less), which is comparable to the estima-
tion from the lymphocyte count (6–20-fold less), whereas
2304 had close to the normal level of rearranged VH genes.
Additional experiments performed using mixtures of cells
with a known proportion of B cells from normal controls
(
 
n
 
 
 
  
 
2) showed that one to two switch fragments could still
be amplified when “normal” B cells constituted as few as
0.15–0.45% of PBL (5–17-fold fewer B cells than present in
411BR). Thus, the reduced number of switch fragments
we observed in the patients is not only due to fewer B cells
but also appears to reflect a reduced number of cells that
had switched to IgA.
Patient 411BR had a reduced serum IgG2 and very low
levels of anti-
 
Pneumococcal
 
 antibody titres before and after vac-
cination (6 and 14 IU/ml, respectively; normal range, 20–
200), which would support the notion of a reduced efficiency
of switching in this patient. Indeed, we could not amplify any
S
 
 
 
–S
 
 
 
2 fragment from this patient using a S
 
 
 
2-specific
primer, whereas in controls (
 
n
 
 
 
  
 
3), an average of 16 frag-
ments could be amplified under the same conditions. Simi-
larly, only one S
 
 
 
–S
 
 
 
2 fragment was amplified from the sec-
ond patient. The numbers of S
 
 
 
–S
 
 
 
1 and S
 
 
 
–S
 
 
 
3 fragments
were also lower in both patients than those from controls (Fig.
S1 C and not depicted), suggesting a parallel reduction in the
number of clones that have switched to IgG in these patients.
 
S
 
 
 
–S
 
 
 
 junctions exhibit long microhomology 
in Lig4D patients
 
The amplified S
 
 
 
–S
 
 
 
 fragment sequences were aligned to
the germline S
 
 
 
 and S
 
 
 
 sequences to define the switch junc-
tions. Altogether, 30 S
 
 
 
–S
 
 
 
 junctions from the Lig4D
patients were characterized (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20040772/DC1). Five
sequences from each patient are shown in Fig. 2. Switching
to 
 
 
 
1 occurred more often than to 
 
 
 
2 both in patients and
controls (60 and 66%, respectively). No sequential switching
through S
 
 
 
 was observed (7% in controls), further support-
ing the notion that there may be a reduction in the effi-
ciency of CSR in these patients, as sequential switching
would involve more than one recombination event.
Next, we analyzed the actual usage of microhomology at
the switch junctions. There was a strikingly high degree of
overlap between the S
 
 
 
 and S
 
 
 
 sequences in switch junctions
derived from the Lig4D patients (9.8 
 
  
 
7.5 vs. 1.8 
 
 
 
 3.2 nu-
cleotides in controls; Student’s 
 
t
 
 test, P 
 
  
 
0.00001). Almost 
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all junctions (29 out of 30; 97%) displayed microhomology of
 
 
 
1 bp (i.e., at least one nucleotide is shared by both the S
 
 
 
and S
 
 
 
 regions; Table I). Moreover, 60% of the junctions ex-
hibited a long microhomology of 
 
 
 
7 bp (Table I). This was
in sharp contrast with S
 
 
 
–S
 
 
 
 junctions derived from normal
donors (Table I), where approximately half (42%) showed no
sequence homology at all and only a minority of the junc-
tions showed a microhomology of 
 
 
 
7 bp (10%). When one
mismatch was allowed at either side of the switch junction,
 
 
 
80% of the switch junctions from the patients were flanked
by 
 
 
 
10/11 bp of imperfect repeats (Table I). The shift in us-
ing long microhomologies or imperfect repeats in the S
 
 
 
–S
 
 
 
junctions from Lig4D patients was even more pronounced
than previously observed in patients with other disorders in-
volving DNA repair (ataxia-telangiectasia [A-T]), Nijmegen
breakage syndrome (NBS) and ataxia-telangiectasia–like dis-
order (ATLD; references 10, 11).
Significantly more S
 
 
 
 breakpoints from the patients (73
vs. 31% in controls) were located in the part of the amplified
S
 
 
 
 region that shows the highest degree of homology with
S
 
 
 
1 or S
 
 
 
2 (position 275-760; 
 
 
 
2
 
 test, P 
 
  
 
0.001; Fig.
S3, available at http://www.jem.org/cgi/content/full/
jem.20040772/DC1). Similar shifts have been described pre-
viously in A-T, NBS, and ATLD patients and PMS2 knock-
out mice, where increased junctional microhomology is also
observed (11, 12). Subsequently, we compared all the junc-
tions with breakpoints within bp 275-760 of the S
 
 
 
 region
from Lig4D patients and controls (22 and 47 junctions, re-
spectively); the junctions from Lig4D patients still exhibited a
significantly higher degree of microhomology in all the cate-
gories (P 
 
  
 
0.01 or P 
 
  
 
0.001). This suggests that clustering
of breakpoints in the part of the S
 
 
 
 where homology to S
 
 
 
 is
most pronounced is due to the need for donor/acceptor ho-
mology in resolving the DSBs associated with IgA switching.
Another feature of the S
 
 
 
–S
 
 
 
 junctions from the Lig4D
patients was a reduction in the number of mutations or in-
sertions at, or around, the breakpoints. We have demon-
strated previously that mutations or insertions frequently oc-
cur close to CSR junctions (
 
 
 
 15 bp; references 11, 13).
However, this was rarely seen in the S
 
 
 
–S
 
 
 
 junctions from
Lig4D patients, where only 3 out of 30 fragments (10%)
showed mutations or insertions in this region (compared
with 56% in controls; 
 
 
 
2
 
 test, P 
 
  0.001).
Point mutations in the germline S  region, which are
probably generated by an AID-dependent process (14, 15),
Figure 2. Sequences of S –S  junctions. The S  and S 1 or S 2 se-
quences are aligned above and below the recombined switch junctional 
sequences. Microhomology was determined by identifying the longest region 
at the switch junction of perfect uninterrupted donor/acceptor identity 
(boxed with solid lines). Imperfect repeat was determined by identifying the 
longest overlap region at the switch junction by allowing one mismatch on 
either side of the breakpoint (the extra nucleotide identity beyond the perfect-
matched sequence identity is boxed by dotted lines). The S  and S  break-
points for each switch fragment are indicated by   and  , respectively, 
and their positions in the germline sequences are indicated on the top or 
below the arrowheads. The number of base pairs involved in microhomology 
and imperfect repeat (numbers indicated in parentheses) for each junction 
is shown at the bottom right of each switch junction.ABERRANT SWITCH JUNCTIONS IN PATIENTS WITH DNA LIGASE IV DEFICIENCY | Pan-Hammarström et al. 192
can also be observed in the recombined S  region, away
from (starting 15-bp upstream) the switch junctions (16). The
pattern of these mutations is similar to those in the V regions
(thus referred to as SHM like). However, they are clearly dif-
ferent from those at, or close to, the switch junctions and oc-
curred at a much lower frequency, suggesting the involve-
ment of a different repair mechanism (11, 16). In Lig4D
patients, SHM-like mutations were observed at a much lower
frequency (1.8/1,000 bp) as compared with those from con-
trols (6.4/1,000 bp,  2 test, P   0.001). Furthermore, the
general pattern of base substitutions was altered, occurring
mainly at A-T sites (56 vs. 37% in controls) and showing a
preference for transitions (78 vs. 59% in controls).
The RGYW/WRCY (R   A or G, Y   C or T, W   A
or T) motifs serve as hotspots for the SHM-like mutations in
the recombined S  region (16, 17) in normal controls. In
Lig4D patients, a similar rate of targeting was observed (72 vs.
70% in controls). Most of the mutations in these motifs are due
to transitions (92 vs. 60% in controls;  2 test, P   0.05) and the
last nucleotide of the motif was more often mutated in the pa-
tients than in controls (38 vs. 5%,  2 test, P   0.001). Although
a diminished rate of CSR or proliferative response may explain
the reduction of SHM-like mutations, this cannot explain the
bias for targeting within the RGYW/WRCY motifs and the
altered pattern of mutations. Thus, like ATM (16), DNA ligase
IV is also, directly or indirectly, involved in the generation of
SHM-like mutations in the S  region.
We further analyzed a few S –S  junctions (n   8) gener-
ated from experiments with a low amount of template DNA
or a reduced proportion of B cells from normal controls. The
nature of these junctions was similar to those amplified under
standard conditions (30 ng of DNA from peripheral blood
cells). Therefore, the aberrant switch junctions derived from
patients are not likely to be due to any bias arising from PCR
amplification when specific target sequences are rare.
S –S  switch junctions show an increased proportion of
1-bp insertions in Lig4D patients
A high proportion of S –S  junctions (n   59) from normal
blood donors display a microhomology of  1 bp; a frequency
similar to, or even higher, than at S –S  junctions (68 vs.
58%; Table I). However, fewer S –S  junctions showed a
microhomology of  4 bp (5 vs. 20%) or  7 bp (0 vs. 10%) as
compared with the corresponding S –S  junctions (Table I).
This is probably due to the low degree of homology between
S  and S  and the likelihood of obtaining a 4-, 7-, 10-, or
15-bp microhomology between the S –S  regions is 1.5,
8.1, 270, and  1,000-fold higher than the S –S  regions.
Mutations or insertions are frequently associated with the
S –S  junctions (  15 bp) in controls (47%). However, the
pattern of nucleotide changes seems to be slightly different
from those associated with the S –S  junctions, with more
mutations occurring at G/C sites (91 vs. 83%) and, although
transitions are preferred (54 vs. 45% in S –S  junctions),
G→T nucleotide changes occur more often at the S –S 
junctions (27 vs. 9%;  2 test, P   0.01). Together, these data
suggest that S –S  junctions may be resolved differently
from S –S  in normal controls.
Subsequently, we cloned and sequenced 36 S –S  frag-
ments from the Lig4D patients. 34 of these fragments were
unique in their junctional sequences and the majority of the
junctions were due to switching to IgG1 (n   18) or IgG3
(n   13). There was a trend toward an increased usage of
microhomologies ( 4 bp) or imperfect repeats ( 4/5 or
 7/8 bp) in the Lig4D patients, but not to a statistically sig-
nificant degree (Table I).
Mutations occurred at a normal frequency around the
S –S  junctions in cells from the Lig4D patients (15 out of
34 fragments; 44 vs. 41% in controls) and no statistically sig-
nificant alteration in the mutation pattern was observed.
However, S –S  junctions from patients exhibited inser-
tions (1 bp) at the breakpoints (Table I) more frequently
than those from controls ( 2 test, P   0.05).
End joining pathways in CSR in Lig4D patients
A number of alternative NHEJ pathways have been pro-
posed in yeast and vertebrates (18). In the former, a Mre11/
Rad50/Rad1–dependent pathway characterized by micro-
homology-mediated end joining, which is only partially de-
pendent on the yeast DNA ligase IV homologue, Dnl4, has
been described previously (19). In vertebrates, substantial ev-
idence exists for an alternative end-joining mechanism that is
Table I. Characterization of S –S  and S –S  junctionsa
Perfectly matched homology Imperfect repeats (with one mismatch)
 1 bp  4 bp  7 bp  10 bp  4/5 bp  7/8 bp  10/11 bp  15/16 bp 1-bp insertion
Total no. of
S junctions
S –S  junctions
Controls 90 (58%) 31 (20%) 16 (10%) 5 (3%) 63 (41%) 34 (22%) 17 (11%) 3 (2%) 39 (25%) 154
Lig4D 29 (97%) 22 (73%) 18 (60%) 14 (47%) 25 (83%) 24 (80%) 24 (80%) 16 (53%) 1 (3%) 30
S –S  junctions
Controls 40 (68%) 3 (5%) 0 (0%) 0 (0%) 10 (17%) 2 (3%) 0 (0%) 0 (0%) 6 (10%) 59
Lig4D 19 (56%) 4 (12%) 0 (0%) 0 (0%) 12 (35%) 3 (9%) 0 (0%) 0 (0%) 11 (32%) 34
aStatistical analysis was performed using  2 test, comparing the number of junctions from the Lig4D patients with the corresponding category of junctions from normal controls. 
For S –S  junctions, in all categories, significant differences (P   0.001) between patients (bold numbers) and controls were observed. For S –S  junctions, a significant 
difference (P   0.05) between patients and controls was observed only in the category with 1-bp insertion (bold). Parts of the data from controls have been described previously 
(references 9–11). The S –S  and S –S  junctions were derived from 17 and 33 normal controls, respectively.JEM VOL. 201, January 17, 2005 193
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independent of the “classical” NHEJ proteins. Thus, end
joining during V(D)J recombination or in various plasmid
assays is inefficient in Ku, DNA ligase IV, or XRCC4-defi-
cient systems, and the recovered junctions occur principally
at short direct repeats with several (usually  4 or  6) base-
pairs of microhomology flanking the DSB (20–23).
The data presented here demonstrate that the resolution
of CSR junctions is significantly altered when DNA ligase
IV function is impaired. Although the S –S  junctions
show considerable donor/acceptor microhomology, far more
than that seen in healthy individuals, the S –S  junctions
show only a trend toward an increase in homology com-
pared with controls. The predominantly used, error-prone,
end joining pathway in CSR appears to be impaired in
Lig4D patients, and the S –S  regions are joined by an al-
ternative, error-free end joining mechanism, involving mi-
crohomology. This alternative mechanism may also be used
in recombination of S –S  regions in the patients, although
to a much lower degree. It is possible that yet another alter-
native pathway is used for joining of the S –S  regions in
Lig4D patients, where 1-bp insertions are frequently intro-
duced. It is worth noting that even in normal controls, the
S –S  and S –S  regions are resolved differently, with
varying degrees of dependence on microhomology and dif-
ferent patterns of junctional mutations, which suggests that
multiple pathways (dominant and alternative) are involved in
resolving the initial lesions in the S regions. The balance in
utilization between these putative different pathways might
depend not only on the factors available but also on the de-
gree of homology between the S regions. It remains unclear
if the alternative mechanisms proposed are totally indepen-
dent of DNA ligase IV, as some residual level of functional
protein might still be present because our patients carry hy-
pomorphic mutations.
A further characteristic of the S –S  junctions in Lig4D
patients is the lack of junctional mutations. This feature has
previously been observed in S –S  junctions from A-T pa-
tients (ATM defective; reference 10), but not those derived
from NBS and ATLD patients (NBS1 and Mre11 defective,
respectively; reference 11), or S –S  junctions from PMS2
deficient mice (12). Therefore, the end joining mechanism,
used in S -S  recombination when ligase IV or ATM is de-
fective, is partially different from the alternative NHEJ path-
ways demonstrated in yeast, where mutations and insertions
are observed along with an increased usage of microhomol-
ogy (19). DNA ligase IV is probably not only necessary in
the final ligation step in CSR, but also, as suggested previ-
ously by in vitro studies, required for alignment-based gap
filling (24). This process involves noncomplementary ends, is
error-prone or imprecise, and could well be accompanied by
recruitment of an error-prone polymerase such as pol  ,
which has previously been implicated in the generation of
mutations in the switch region (25).
In conclusion, the involvement of DNA ligase IV in
CSR is clearly demonstrated by the altered pattern of in vivo
recombination at the switch junctions. Three components of
NHEJ (DNA-PKcs, Ku70, and Ku 80) have previously been
implicated in CSR. However, as both Ku and DNA PKcs
display additional NHEJ-independent functions (3), it is un-
certain whether the CSR defects observed in Ku and DNA-
PKcs knockout mice are due to an impairment of the NHEJ
pathway. Because DNA ligase IV and XRCC4 have no re-
ported roles outside NHEJ, our study links DNA ligase IV
and, therefore NHEJ, to CSR.
MATERIALS AND METHODS
Patients. Two out of the four DNA ligase IV–defective (Lig4D) patients
characterized previously (7) were included in this study. Patient 411BR carries
three homozygous alterations in LIG4 and the second patient (2304), from an
independent family with two affected siblings, is a compound heterozygote for
two truncating mutations (7). Patient 411BR was reported to have pancytope-
nia (7), at the time of sampling having 0.37   109 cells/ml of lymphocytes
with a lowered proportion (2.6%) of B cells. Pretreatment Ig level determina-
tion showed that IgG2 was below the normal range; the patient is currently
being treated with regular immunoglobulin infusions. Patient 2304 had
chronic respiratory infections and “bone marrow failure” although the lineages
affected were not clearly stated at the time. Previous records on Ig levels or
lymphocyte counts were not available from this patient. The institution review
boards at the Karolinska Institute approved the study.
Amplification of switch (S) –S  and S –S  fragments. Genomic
DNA was purified from peripheral blood cells from patients and healthy
blood donors. The amplification of S –S  fragments was performed as de-
scribed previously (8, 10). In brief, two pairs of S  and S -specific primers
were used in a nested PCR assay (Fig. S1 A). The number of S –S  frag-
ments was determined from 10 reactions run in parallel using DNA (30 ng
per reaction) from each individual and represents random amplification of
in vivo–switched clones. The PCR error rate was estimated previously
(0.9/1,000 nucleotides; reference 8).
CD19-positive B cells were isolated from peripheral blood mononuclear
cells from normal individuals using Dynabeads M-450 CD19 (Dynal). Geno-
mic DNA was extracted from the positively isolated B cells and the negatively
isolated non–B cell populations from the same individual. The VH-FR3-JH
rearrangements were PCR amplified as described previously (26).
The S –S 3 fragments were amplified as described previously (9) and
two new primers, S 1 specific (5 -ACGTCGACGCCCTCAGCTGTC-
TGTT-3 ) and S 2 specific (5 -GTCTGCAGTGTGGCTGCTCTG-
CTCTGAT-3 ) were applied to allow detection of switching to IgG1 and
IgG2, respectively.
Analysis of the S –S  and S –S  junctions. The PCR-amplified S –
S  and S –S  fragments were purified, cloned, and sequenced as described
previously (8). The breakpoints were determined by aligning the switch frag-
ment sequences with the S  (X54713)/S 1 (L19121)/S 2 (AF030305) or
S /S 1 (U39737)/S 2 (U39934)/S 3 (U39935)/S 4 (Y12547-52; refer-
ence 27) sequences. Microhomology was defined as successive nucleotides
that were shared by both the S  and S  or S  regions at the switch junction
(without mismatches). The term imperfect repeat was used when one mis-
match was allowed adjacent to the breakpoint. Insertion was defined as a nu-
cleotide at the breakpoints that was not identical to either of the switch re-
gions. Mutation close to, or at, the junction was defined as a nucleotide
change within 15 bp on either side of the switch junction. Polymorphisms in
the switch regions were excluded from the mutation analysis.
Online supplemental material. Fig. S1 describes the PCR strategy for
amplification of S –S  and S –S  fragments and estimation of the input of
DNA templates. The sequences for all the S –S  junctions are presented in
Fig. S2. Distribution of the S –S  breakpoints is given in Fig. S3. Online
supplemental material is available at http://www.jem.org/cgi/content/full/
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